Department of Medicine, University of South Carolina School of Medicine, Columbia, South Carolina.
Department of Medicine, University of South Carolina School of Medicine, Columbia, South Carolina.
Am J Med Sci. 2019 Feb;357(2):160-163. doi: 10.1016/j.amjms.2018.10.014. Epub 2018 Nov 1.
Iron deficiency anemia is often listed among potential adverse effects of gastric acid-suppressive medications, given that gastric acidity promotes intestinal absorption of nonheme iron. Additionally, the antacid calcium carbonate can inhibit iron absorption. However, there is little direct clinical evidence that proton-pump inhibitors, histamine-2 receptor antagonists, or calcium carbonate cause iron deficiency anemia. Most case reports have had substantial limitations (e.g., minimal follow-up and presence of other causes of iron deficiency), and retrospective cohort studies have lacked sufficient patient-specific detail to make strong causal inferences. We present 2 cases-both with detailed, prospective 10-year follow-up-in which combinations of proton-pump inhibitors, histamine-2 receptor antagonists and calcium carbonate were clearly associated with development of iron deficiency anemia. Overt iron-deficiency anemia is probably uncommon in patients who use acid-modifying medications and who have no other conditions that predispose to iron deficiency. Nevertheless, clinicians should be aware of this potential complication, given widespread use of these agents.
缺铁性贫血常被列为胃酸抑制药物的潜在不良反应之一,因为胃酸有助于非血红素铁的肠道吸收。此外,抗酸剂碳酸钙可以抑制铁的吸收。然而,几乎没有直接的临床证据表明质子泵抑制剂、组胺 2 受体拮抗剂或碳酸钙会导致缺铁性贫血。大多数病例报告都存在很大的局限性(例如,随访时间短,存在其他缺铁原因),回顾性队列研究缺乏足够的患者具体细节,无法做出强有力的因果推断。我们提出了 2 个病例,均进行了详细的、前瞻性的 10 年随访,其中质子泵抑制剂、组胺 2 受体拮抗剂和碳酸钙的联合使用与缺铁性贫血的发生明显相关。明显的缺铁性贫血在使用酸调节药物且没有其他易患缺铁的疾病的患者中可能并不常见。然而,鉴于这些药物的广泛应用,临床医生应该意识到这种潜在的并发症。